BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

...HA elicited similar titers of neutralizing antibodies against HA as intramuscular injection of flu vaccine Afluria...
BioCentury | Oct 3, 2016
Clinical News

Afluria Quadrivalent: Phase III data

...from a double-blind, U.S. Phase III trial in 2,278 children ages 5-17 showing that intramuscular Afluria...
...Data were presented at the Options IX for the Control of Influenza meeting in Chicago. Afluria...
...viruses contained in the vaccine in people ages >=18. CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Afluria...
BioCentury | Oct 3, 2016
Clinical News

Afluria Quadrivalent: Phase III data

...adults ages >=18 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferiority to Afluria...
...Data were presented at the Options IX for the Control of Influenza meeting in Chicago. Afluria...
...viruses contained in the vaccine in people ages >=18. CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Afluria...
BioCentury | Sep 5, 2016
Clinical News

Afluria Quadrivalent regulatory update

...FDA approved an sBLA from CSL’s Seqirus unit for Afluria Quadrivalent to prevent infection from 2...
...Afluria will be available during the 2016-17 flu season. Both products are inactivated influenza vaccines; Afluria...
...see BioCentury, Nov. 3, 2014 & Sept. 14, 2015). CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Afluria...
BioCentury | Sep 15, 2014
Clinical News

Afluria regulatory update

...approved the PharmaJet Stratis 0.5 mL Needle-Free Jet Injector from PharmaJet for delivery of bioCSL's Afluria...
...Afluria, a trivalent inactivated influenza vaccine, in the U.S. CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Afluria...
BioCentury | Oct 31, 2011
Clinical News

Influenza vaccines infectious data

...in The Lancet. Marketed TIVs include Fluvirin from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and Afluria...
BioCentury | Jul 4, 2011
Clinical News

Afluria regulatory update

...a warning letter from FDA relating to deviations in cGMP practices in the manufacture of Afluria...
...plans to "work diligently" with the agency to resolve the issues as quickly as possible. Afluria...
...NYSE:MRK, Whitehouse Station, N.J.) markets Afluria in the U.S. CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Afluria...
BioCentury | Aug 9, 2010
Clinical News

Afluria regulatory update

...FDA updated the label for CSL's Afluria to warn that the trivalent inactivated seasonal influenza vaccine...
...formulation of the vaccine. FDA said it is requiring CSL to conduct a study of Afluria...
...Afluria in the U.S (see BioCentury, Oct. 5, 2009). CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Afluria...
BioCentury | Nov 16, 2009
Clinical News

Afluria regulatory update

...FDA granted accelerated approval to expand the label for CSL's Afluria trivalent inactivated seasonal influenza vaccine...
...market Afluria in the U.S (see BioCentury, Oct. 5). CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Afluria...
BioCentury | Oct 5, 2009
Company News

CSL, Merck sales and marketing update

...Merck received an exclusive license to market CSL's seasonal influenza H1N1 vaccine Afluria in the U.S...
Items per page:
1 - 10 of 17